Stimulant

Global Biostimulants Market 2020-2025 by Active Ingredient, Application Method, Crop Type, Form - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 29, 2020
Health, General Health, Attention deficit hyperactivity disorder, Psychopharmacology, Stimulant, Fertilizer, Agroecology, Sustainable technologies, Articles, Agriculture and the environment, Agriculture, Bioeffector

The "Global Biostimulants Market 2020-2025 by Active Ingredient, Application Method, Crop Type, Form, Geography and Impact of Covid-19 with Ansoff's Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biostimulants Market 2020-2025 by Active Ingredient, Application Method, Crop Type, Form, Geography and Impact of Covid-19 with Ansoff's Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Bio-stimulants are substances used in agriculture to promote plant growth without the use of any fertilizers.
  • They are available in many formulations of compounds, substances, and micro-organisms to ensure a good crop vigor.
  • On the contrary, factors affecting this growth is the lack of awareness amongst the farmers about the benefits of bio-stimulants.

NutraIngredients-USA Awards 2020 Sports Nutrition Ingredient of the Year to Nutrition21's nooLVL®

Retrieved on: 
Tuesday, July 21, 2020
eSports, Video game culture, Stimulant

HARRISON, N.Y., July 21, 2020 /PRNewswire/ --Nutrition21 has proudly accepted the NutraIngredients-USA 2020 Ingredient of the Year: Sports Nutritionfor its novel new ingredientnooLVL.

Key Points: 
  • HARRISON, N.Y., July 21, 2020 /PRNewswire/ --Nutrition21 has proudly accepted the NutraIngredients-USA 2020 Ingredient of the Year: Sports Nutritionfor its novel new ingredientnooLVL.
  • Given the success of this study, Nutrition21 plans to fund additional studies on nooLVL to further demonstrate the potential benefits this ingredient can provide.
  • About nooLVL: nooLVL is a patented, non-stimulant, nutritional ingredient that boosts cognitive performance and energy in esports athletes.
  • The first esports gaming ingredient from Nutrition21, nooLVL is both fast and effective - working within 15 minutes and increasing perceived energy, focus and accuracy.

Adlon Therapeutics L.P. and the Prescription Drug Safety Network Launch New Resources to Encourage Safe and Responsible Use of Prescription Stimulant Medications

Retrieved on: 
Tuesday, July 21, 2020
Technology, Biotechnology, Audio, Video, Health, Consumer, Pharmaceutical, Other Education, Other Science, Mental health, Research, Parenting, Education, General Health, Science, Health, Clinical pharmacology, Pharmacy, Pharmaceuticals policy, Symbols, Medical prescription, Patient safety, Stimulant, Prescription drug

In July 2019, Adlon Therapeutics joined the Network with a commitment to support EVERFIs efforts to deliver its innovative, evidence-based curriculum to high school students.

Key Points: 
  • In July 2019, Adlon Therapeutics joined the Network with a commitment to support EVERFIs efforts to deliver its innovative, evidence-based curriculum to high school students.
  • Were excited to work with the Network to introduce relatable, interactive content on prescription stimulant medications for patients and their families.
  • This work is part of our ongoing commitment to supporting efforts to address prescription drug misuse.
  • Providing critical information about stimulant medications in particular is so important to reducing prescription drug misuse in this country.

Praxis Bioresearch Announces Issuance of U.S. Patent on its Prodrug Stimulant PRX-P4-003

Retrieved on: 
Tuesday, June 23, 2020
PRX, Stimulant, Praxis

PRX-P4-003is a new chemical entity (NCE) that incorporates an active isomer of fencamfamine, a well-tolerated Schedule IV stimulant.

Key Points: 
  • PRX-P4-003is a new chemical entity (NCE) that incorporates an active isomer of fencamfamine, a well-tolerated Schedule IV stimulant.
  • Praxis plans to develop the prodrug for underserved medical needs in binge eating disorder as well as apathy in Alzheimers disease.
  • We believe that Prodrug PRX-P4-003 mechanism elegantly taps into proven therapeutic benefit of stimulant activity with a significantly reduced abuse risk, said Sandeep Patil, PhD, MD, chief executive officer of Praxis Bioresearch.
  • The content of this press release is solely the responsibility of Praxis Bioresearch and does not necessarily represent the official views of the NIH.

Gelesis Announces Partnership for Commercial Launch of Plenity® in China

Retrieved on: 
Thursday, June 18, 2020
Biotechnology, Pharmaceutical, Health, FDA, Diabetes, Fitness & Nutrition, Clinical trials, Other Health, Medicine, Articles, Health, Attention deficit hyperactivity disorder, Psychopharmacology, Stimulant, Overweight, Chronic condition, Obesity, Plenity®, Gelesis, CMS

Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat overweight, obesity and other chronic metabolic diseases, today announced a partnership with China Medical System Holdings Limited (CMS) (HKG:0867) for the commercialization of Plenity in China.

Key Points: 
  • Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat overweight, obesity and other chronic metabolic diseases, today announced a partnership with China Medical System Holdings Limited (CMS) (HKG:0867) for the commercialization of Plenity in China.
  • Plenity will complement CMSs strong record of prescription and healthcare licensing launches in China.
  • Plenity, the first product based on Gelesis proprietary hydrogel technology platform, is an orally-administered, non-systemic and non-stimulant aid for weight management.
  • China Medical System Holdings Limited (CMS) is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China.

Concern raised over fatally injured fatigued drivers who also tested positive for drugs

Retrieved on: 
Monday, March 9, 2020
Neurochemistry, Drugs, Psychoactive drugs, GABAA receptor positive allosteric modulators, Attention deficit hyperactivity disorder, Psychopharmacology, Stimulant, Depressant, Sleep-deprived driving, Alcohol, Effects of fatigue on safety, Narcotic

Data from TIRFs National Fatality Database are included to describe trends in driver fatigue among fatally injured victims, and the characteristics of fatigued drivers dying in road crashes.

Key Points: 
  • Data from TIRFs National Fatality Database are included to describe trends in driver fatigue among fatally injured victims, and the characteristics of fatigued drivers dying in road crashes.
  • Of concern, 40.8% of fatally injured fatigued drivers tested positive for drugs, and 22.2% of these drivers tested positive for alcohol.
  • In addition, results showing more than 40% of fatally injured fatigued drivers also tested positive for marijuana, CNS depressants, CNS stimulants and narcotic analgesics are concerning.
  • Additionally, the data suggest four out of ten fatally injured drivers who were fatigued also tested positive for drugs demonstrating a crucial need for further monitoring of this issue.

NAO® Brain Stimulation Soon Will Be Food For Thought in the United States

Retrieved on: 
Thursday, March 5, 2020
Branches of biology, Biology, Neuroscience, Sleep deprivation, Sleep, Fatigue, Stimulant

NAO Brain Stimulation is the first natural brain food that helps with cognitive performance and reduces fatigue, said Annette Steiner-Kienzler, product developer and pharmacist for Germany-based R-Pharm.

Key Points: 
  • NAO Brain Stimulation is the first natural brain food that helps with cognitive performance and reduces fatigue, said Annette Steiner-Kienzler, product developer and pharmacist for Germany-based R-Pharm.
  • We developed the first natural stimulant that provides an immediate effect it should keep you awake for about eight hours.
  • R-Pharm plans to bring NAO to the U.S. market in the coming months.
  • Lack of sleep is at epidemic levels in the United States with 54 percent of people getting less than six hours or less of sleep.

Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD

Retrieved on: 
Tuesday, January 21, 2020
Health, Drugs, Psychoactive drugs, Amphetamine, TAAR1 agonists, Pharmaceuticals policy, Biogenic amines, Neurotransmitters, Prescription Drug User Fee Act, Stimulant, Attention deficit hyperactivity disorder, Medication

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 8, 2020.

Key Points: 
  • The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 8, 2020.
  • SPN-812, if approved by the FDA, will be the first truly new therapy to treat ADHD in a decade, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.
  • SPN-812 is a serotonin norepinephrine modulating agent (SNMA) that Supernus is developing as a novel non-stimulant for the treatment of ADHD.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Study 2019: Includes Historic Industry Data from 2016 and Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 20, 2019
Health, Pharmaceutical, Attention deficit hyperactivity disorder, Psychiatry, Neuroscience, Psychiatric diagnosis, Health, Childhood psychiatric disorders, Amphetamine, Educational psychology, Developmental disorder, Stimulant, Attention deficit hyperactivity disorder controversies, Adult attention deficit hyperactivity disorder

The "Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment" report has been added to ResearchAndMarkets.com's offering.
  • The Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment market is expected to reach $34.1 billion by 2026 growing at a CAGR of 7.7% during the forecast period.
  • Increasing awareness regarding neuro-developmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth.
  • However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.

Lavie Bio Announces Advancement in Its Product Development Pipeline for Wheat Bio-stimulants

Retrieved on: 
Monday, November 18, 2019
Evogene, Rehovot, Lavie, Stimulant, Tel Aviv Stock Exchange, Stock exchanges, Companies, Middle East

REHOVOT, Israel, Nov. 18, 2019 /PRNewswire/ --Lavie Bio (Lavie), a subsidiary of Evogene (NASDAQ: EVGN) (TASE: EVGN), aiming to improve food quality, sustainability and agriculture productivity through the introduction of microbiome based ag-biological products, announces today phase advancement in its product development pipeline for wheat bio-stimulants.

Key Points: 
  • REHOVOT, Israel, Nov. 18, 2019 /PRNewswire/ --Lavie Bio (Lavie), a subsidiary of Evogene (NASDAQ: EVGN) (TASE: EVGN), aiming to improve food quality, sustainability and agriculture productivity through the introduction of microbiome based ag-biological products, announces today phase advancement in its product development pipeline for wheat bio-stimulants.
  • Lavie Bio is advancing its leading product candidate LAV211into 'development stage 2', while continuing the development of its additional product candidates LAV212and LAV213.
  • This is a significant addressable market for Lavie Bio, whose wheat bio-stimulant products have the potential to increase farmer's profits by $20-$50 per acre through yield gains.
  • In parallel, Lavie Bio will further advance the development of LAV 212,213 as basis for future potential new products.